BullFrog AI Holdings Inc. has announced the publication of a new whitepaper detailing the scientific advances of its AI-driven technologies in bioinformatics. The company's research highlights how its BullFrog Data Networks® and bfLEAP® platform address major challenges in drug discovery by transforming complex biological data into actionable insights. The whitepaper outlines how BullFrog AI's causal inference and probabilistic validation methods, originally developed at the Johns Hopkins Applied Physics Laboratory, improve the reliability of target identification, biomarker discovery, and patient stratification. These results have already been published in the new whitepaper, which is available for download.